OpenMask3D: Open-Vocabulary 3D Instance Segmentation

We introduce the task of open-vocabulary 3D instance segmentation. Traditional approaches for 3D instance segmentation largely rely on existing 3D annotated datasets, which are restricted to a closed-set of object categories. This is an important limitation for real-life applications where one might need to perform tasks guided by novel, open-vocabulary queries related to objects from a wide variety. Recently, open-vocabulary 3D scene understanding methods have emerged to address this problem by learning queryable features per each point in the scene. While such a representation can be directly employed to perform semantic segmentation, existing methods have limitations in their ability to identify object instances. In this work, we address this limitation, and propose OpenMask3D, which is a zero-shot approach for open-vocabulary 3D instance segmentation. Guided by predicted class-agnostic 3D instance masks, our model aggregates per-mask features via multi-view fusion of CLIP-based image embeddings. We conduct experiments and ablation studies on the ScanNet200 dataset to evaluate the performance of OpenMask3D, and provide insights about the open-vocabulary 3D instance segmentation task. We show that our approach outperforms other open-vocabulary counterparts, particularly on the long-tail distribution. Furthermore, OpenMask3D goes beyond the limitations of close-vocabulary approaches, and enables the segmentation of object instances based on free-form queries describing object properties such as semantics, geometry, affordances, and material properties.Comment: project page: https://openmask3d.github.io

A Time-Space Tradeoff for the Sumcheck Prover

The sumcheck protocol is an interactive protocol for verifying the sum of a low-degree polynomial over a hypercube. This protocol is widely used in practice, where an efficient implementation of the (honest) prover algorithm is paramount. Prior work contributes highly-efficient prover algorithms for the notable special case of multilinear polynomials (and related settings): [CTY11] uses logarithmic space but runs in superlinear time; in contrast, [VSBW13] runs in linear time but uses linear space. In this short note, we present a family of prover algorithms for the multilinear sumcheck protocol that offer new time-space tradeoffs. In particular, we recover the aforementioned algorithms as special cases. Moreover, we provide an efficient implementation of the new algorithms, and our experiments show that the asymptotics translate into new concrete efficiency tradeoffs

Protection against pertussis in humans correlates to elevated serum antibodies and memory B cells

Pertussis is a respiratory infection caused by Bordetella pertussis that may be particularly severe and even lethal in the first months of life when infants are still too young to be vaccinated. Adults and adolescents experience mild symptoms and are the source of infection for neonates. Adoptive maternal immunity does not prevent pertussis in the neonate. We compared the specific immune response of mothers of neonates diagnosed with pertussis and mothers of control children. We show that women have pre-existing pertussis-specific antibodies and memory B cells and react against the infection with a recall response increasing the levels specific serum IgG, milk IgA, and the frequency of memory B cells of all isotypes. Thus, the maternal immune system is activated in response to pertussis and effectively prevents the disease indicating that the low levels of pre-formed serum antibodies are insufficient for protection. For this reason, memory B cells play a major role in the adult defense. The results of this study suggest that new strategies for vaccine design should aim at increasing long-lived plasma cells and their antibodies

Infants hospitalized for Bordetella pertussis infection commonly have respiratory viral coinfections

Background: Whether viral coinfections cause more severe disease than Bordetella pertussis (B. pertussis) alone remains unclear. We compared clinical disease severity and sought clinical and demographic differences between infants with B. pertussis infection alone and those with respiratory viral coinfections. We also analyzed how respiratory infections were distributed during the 2 years study. Methods: We enrolled 53 infants with pertussis younger than 180 days (median age 58 days, range 17–109 days, 64. 1% boys), hospitalized in the Pediatric Departments at “Sapienza” University Rome and Bambino Gesù Children’s Hospital from August 2012 to November 2014. We tested in naso-pharyngeal washings B. pertussis and 14 respiratory viruses with real-time reverse-transcriptase-polymerase chain reaction. Clinical data were obtained from hospital records and demographic characteristics collected using a structured questionnaire. Results: 28/53 infants had B. pertussis alone and 25 viral coinfection: 10 human rhinovirus (9 alone and 1 in coinfection with parainfluenza virus), 3 human coronavirus, 2 respiratory syncytial virus. No differences were observed in clinical disease severity between infants with B. pertussis infection alone and those with coinfections. Infants with B. pertussis alone were younger than infants with coinfections, and less often breastfeed at admission. Conclusions: In this descriptive study, no associations between clinical severity and pertussis with or without co-infections were found

Evaluation and validation of an alternative method to detect Campylobacter spp. in dairy products

Foods implicated in human campylobacteriosis include raw or undercooked poultry and raw dairy products. Because Campylobacter spp. are the most frequently reported cause of bacterial infection in the European Union and because conventional methods are cumbersome, rapid methods for Campylobacter detection and quantification in food are needed. With this study we sought to validate, according to the standard procedure (UNI EN ISO 16140:2003), an alternative to the reference analytical method (UNI EN ISO 10272- 1:2006) for official controls of Campylobacter spp. in raw milk and dairy products. Milk samples collected from 16 milk vending machines located throughout the Genoa metropolitan area were analyzed using two different methods, an enzymelinked fluorescent assay (ELFA) and a real-time PCR assay, and evaluated in parallel against the reference method. In addition, a total of 460 samples of raw milk collected from milk vending machines were analyzed by ELFA. Results obtained with ELFA showed it was compliant with UNI EN ISO 10272-1:2006 criteria and that the immunoassay had 100% sensitivity, specificity, and accuracy. Regarding samples of milk vending machines, 5.0% (23/460) tested positive at ELFA screening and were subsequently confirmed as C. jejuni. Validation according to UNI EN ISO 16140:2003 of the ELFA method suggests it may be a useful alternative to conventional methods for detecting Campylobacter spp. in official controls

Empirical determination of the lithium 6707.856 Å wavelength in young stars

Absorption features in stellar atmospheres are often used to calibrate photocentric velocities for the kinematic analysis of further spectral lines. The Li feature at ∼6708 Å is commonly used, especially in the case of young stellar objects, for which it is one of the strongest absorption lines. However, this complex line comprises two isotope fine-structure doublets. We empirically measured the wavelength of this Li feature in a sample of young stars from the PENELLOPE/VLT programme (using X-shooter, UVES, and ESPRESSO data) as well as HARPS data. For 51 targets, we fit 314 individual spectra using the STAR-MELT package, resulting in 241 accurately fitted Li features given the automated goodness-of-fit threshold. We find the mean air wavelength to be 6707.856 Å, with a standard error of 0.002 Å (0.09 km s−1), and a weighted standard deviation of 0.026 Å (1.16 km s−1). The observed spread in measured positions spans 0.145 Å, or 6.5 km s−1, which is higher by up to a factor of six than the typically reported velocity errors for high-resolution studies. We also find a correlation between the effective temperature of the star and the wavelength of the central absorption. We discuss that exclusively using this Li feature as a reference for photocentric velocity in young stars might introduce a systematic positive offset in wavelength to measurements of further spectral lines. If outflow tracing forbidden lines, such as [O 

A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience

We addressed trastuzumab emtansine (T-DM1) efficacy in HER2+ metastatic breast cancer patients treated in real-world practice, and its activity in pertuzumab-pretreated patients. We conducted a retrospective, observational study involving 23 cancer centres, and 250 patients. Survival data were analyzed by Kaplan Meier curves and log rank test. Factors testing significant in univariate analysis were tested in multivariate models. Median follow-up was 15 months and median T-DM1 treatment-length 4 months. Response rate was 41.6%, clinical benefit 60.9%. Median progression-free and median overall survival were 6 and 20 months, respectively. Overall, no differences emerged by pertuzumab pretreatment, with median progression-free and median overall survival of 4 and 17 months in pertuzumab-pretreated (p=0.13), and 6 and 22 months in pertuzumab-na\uc3\uafve patients (p=0.27). Patients who received second-line T-DM1 had median progression-free and median overall survival of 3 and 12 months (p=0.0001) if pertuzumab-pretreated, and 8 and 26 months if pertuzumab-na\uc3\uafve (p=0.06). In contrast, in third-line and beyond, median progression-free and median overall survival were 16 and 18 months in pertuzumab-pretreated (p=0.05) and 6 and 17 months in pertuzumab-na\uc3\uafve patients (p=0.30). In multivariate analysis, lower ECOG performance status was associated with progression-free survival benefit (p < 0.0001), while overall survival was positively affected by lower ECOG PS (p < 0.0001), absence of brain metastases (p 0.05), and clinical benefit (p < 0.0001). Our results are comparable with those from randomized trials. Further studies are warranted to confirm and interpret our data on apparently lower T-DM1 efficacy when given as second-line treatment after pertuzumab, and on the optimal sequence order